Avicanna Welcomes Initial U.S. Rescheduling of Medical Cannabis & Provides Scientific Update
Rescheduling aligns with Avicanna’s established pharmaceutical and medical cannabis strategyRescheduling further supports advancement of R&D, clinical development, and medical affairs initiatives TORONTO, April 28, 2026 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avic…
Strategic OutlookThe evolving U.S. regulatory framework represents a significant milestone in the integration of cannabinoid-based therapeutics within a pharmaceutical framework. Avicanna will contin…